Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: J Endocrinol. 2014 Jul;222(1):27–41. doi: 10.1530/JOE-13-0455

Figure 3.

Figure 3

Change in body weight (Top) and daily food consumption (Bottom) following administration of control vector to MBH and VTA (squares), rAAV-leptin to VTA with rAAV-control to MBH (circles) or rAAV-leptin to VTA simultaneously with rAAV-leptin antagonist to MBH (rAAV-Leptin VTA/Antg MBH, triangles). The rAAV-vectors were administered at day 0. Values represent the mean ± SE of 7-8 rats per group.

Top: Delta body weight significantly diverged from controls starting at day 5 in the rAAV-Leptin VTA treated group (*P<0.01), at day 6 in rAAV-Leptin VTA /Antg MBH treated group (*P<0.01). The latter group was significantly different from both the controls and rAAV-leptin group starting at day 9 (†P<0.02) by one-way ANOVA and Newman-Keuls post-hoc analysis.

Bottom: Food consumption significantly diverged from controls starting at day 4 in the rAAV-Leptin VTA treated group (*P<0.001) and in rAAV-Leptin VTA /Antg MBH treated group (*P<0.01). The latter group was significantly different from both the control and the rAAV-leptin group starting at day 7 (†P<0.05) by one-way ANOVA and Newman-Keuls post-hoc analysis.